Latest Insider Transactions at Provention Bio, Inc. (PRVB)
This section provides a real-time view of insider transactions for Provention Bio, Inc. (PRVB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Provention Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Provention Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 27
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,567,497
-100.0%
|
-
|
|
Apr 27
2023
|
Ashleigh Palmer Director and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,570,050
-100.0%
|
-
|
|
Apr 27
2023
|
Wayne Pisano Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,500
-100.0%
|
-
|
|
Apr 27
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,500,000
-100.0%
|
-
|
|
Apr 27
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
73,000
-100.0%
|
-
|
|
Apr 27
2023
|
Eleanor Ramos Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
70,000
-100.0%
|
-
|
|
Apr 27
2023
|
Avery W Catlin Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
20,000
-100.0%
|
-
|
|
Apr 21
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
224,617
-100.0%
|
-
|
|
Apr 20
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
202,314
-47.39%
|
-
|
|
Apr 14
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,190,549
-12.34%
|
$52,573,176
$24.32 P/Share
|
|
Apr 14
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
8,879,023
+33.33%
|
$53,274,138
$6.0 P/Share
|
|
Apr 13
2023
|
Francisco Leon Chief Scientific Officer |
BUY
Bona fide gift
|
Indirect |
1,500,000
+95.36%
|
-
|
|
Apr 13
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
1,500,000
-95.36%
|
-
|
|
Apr 13
2023
|
Avery W Catlin Director |
BUY
Bona fide gift
|
Indirect |
10,000
+50.0%
|
-
|
|
Apr 13
2023
|
Avery W Catlin Director |
SELL
Bona fide gift
|
Direct |
10,000
-50.0%
|
-
|
|
Apr 04
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Bona fide gift
|
Direct |
218,651
-33.87%
|
-
|
|
Mar 31
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
3,000,000
-25.25%
|
-
|
|
Feb 13
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,985
-1.63%
|
$259,850
$10.04 P/Share
|
|
Feb 13
2023
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,985
+1.6%
|
$51,970
$2.5 P/Share
|
|
Feb 13
2023
|
Ashleigh Palmer Director and CEO |
SELL
Open market or private sale
|
Direct |
25,835
-1.0%
|
$258,350
$10.04 P/Share
|
|
Feb 13
2023
|
Ashleigh Palmer Director and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,835
+0.99%
|
$51,670
$2.5 P/Share
|
|
Feb 10
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
50,000
-3.08%
|
$500,000
$10.11 P/Share
|
|
Feb 10
2023
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+2.99%
|
$100,000
$2.5 P/Share
|
|
Feb 10
2023
|
Jason Hoitt Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,500
-100.0%
|
$45,000
$10.0 P/Share
|
|
Feb 10
2023
|
Ashleigh Palmer Director and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-1.91%
|
$500,000
$10.11 P/Share
|
|
Feb 10
2023
|
Ashleigh Palmer Director and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+1.87%
|
$100,000
$2.5 P/Share
|
|
Jan 18
2023
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
24,015
-1.5%
|
$240,150
$10.27 P/Share
|
|
Jan 18
2023
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,015
+1.48%
|
$48,030
$2.5 P/Share
|
|
Jan 18
2023
|
Ashleigh Palmer Director and CEO |
SELL
Open market or private sale
|
Direct |
24,165
-0.93%
|
$241,650
$10.27 P/Share
|
|
Jan 18
2023
|
Ashleigh Palmer Director and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
24,165
+0.92%
|
$48,330
$2.5 P/Share
|
|
Jan 18
2023
|
Sessa Capital (Master), L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,000,000
-20.16%
|
$27,000,000
$9.4 P/Share
|
|
Dec 29
2022
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
187,000
-10.63%
|
$1,870,000
$10.26 P/Share
|
|
Dec 29
2022
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
187,000
+9.6%
|
$374,000
$2.5 P/Share
|
|
Dec 27
2022
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,674
-0.67%
|
$106,740
$10.0 P/Share
|
|
Dec 27
2022
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,674
+0.67%
|
$21,348
$2.5 P/Share
|
|
Dec 23
2022
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
375
-0.02%
|
$3,750
$10.0 P/Share
|
|
Dec 23
2022
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
375
+0.02%
|
$750
$2.5 P/Share
|
|
Dec 22
2022
|
Francisco Leon Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,568
-0.1%
|
$15,680
$10.0 P/Share
|
|
Dec 22
2022
|
Francisco Leon Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,568
+0.1%
|
$3,136
$2.5 P/Share
|
|
Dec 03
2021
|
Eleanor Ramos Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,201
+6.92%
|
$31,206
$6.49 P/Share
|
|
Nov 30
2021
|
Ashleigh Palmer Director and CEO |
BUY
Open market or private purchase
|
Direct |
3,750
+0.15%
|
$22,500
$6.66 P/Share
|
|
Nov 24
2021
|
Francisco Leon Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
5,550
+0.22%
|
$38,850
$7.24 P/Share
|
|
Jul 19
2018
|
Johnson & Johnson > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,400,000
+50.0%
|
-
|